Short answer
MapLight Therapeutics, Inc. (MPLT) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). No substantive material agreement terms disclosed in the provided Item 1.01 excerpt.
MapLight Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- No substantive material agreement terms disclosed in the provided Item 1.01 excerpt
- Investor impact cannot be assessed without the referenced agreement or additional filing details
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 filing contains only an exhibit incorporation disclaimer
- No operating results, financial figures, or fiscal-year performance details available in the provided text
- Investors should consult the referenced exhibit for the substantive earnings disclosure
Item 3.02 · Unregistered Sales of Equity Securities
- Purchase Agreement covers securities to be sold and issued by MapLight Therapeutics
- Item 3.02 signals an unregistered equity issuance, potentially creating dilution for existing shareholders
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation for investor and analyst meetings
- Presentation furnished as Exhibit 99.3 and available on the company website
- Reg FD disclosure indicates investor-facing messaging or data was refreshed
Item EX-99.1 · Exhibit EX-99.1
- Positive Phase 2 ZEPHYR results support planned registrational Phase 3 ZEPHYR-2 in schizophrenia, with topline results expected in 2028
- ML-007C-MA advanced as the lead asset across schizophrenia and ADP; VISTA enrollment ongoing with results expected in the second half of 2027
- ML-004 missed its primary ASD social-communication endpoint, shifting focus toward adolescent irritability and potential partnerships or funding
- Cash, equivalents and investments of $351.3M plus a $150M private placement expected to fund ML-007C-MA programs through 2028
- Second-quarter net loss widened to $60.2M from $29.8M, while R&D expense rose to $53.4M from $26.8M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MapLight Therapeutics, Inc. 8-K filings
Get the next MPLT 8-K as it lands
Follow MPLT for push alerts, or ask the research agent what this filing means.